Safety under the regulatory spotlight — 215 documents in 90 days

101 documents in the last 30 days alone

This concentration of safety-related regulatory documents may indicate a tightening cycle, particularly if the recent surge reflects more frequent guidance, enforcement themes, or heightened scrutiny of benefit-risk evidence and post-market obligations. Companies with safety programs should consider watching for shifts in signal detection expectations, pharmacovigilance reporting thresholds, labeling updates, and any new emphasis on real-world evidence or class-wide risk management, as this could suggest regulators are becoming less tolerant of ambiguity in safety narratives.